Cavinton, pills 5mg, 50pcs

Composition

Active ingredient:

vinpocetine 5 mg

Pharmacological action

A drug that improves cerebral circulation and brain metabolism.

Increases the consumption of glucose and oxygen by brain tissue.

Increases the resistance of neurons to hypoxia; increases the transport of glucose to the brain through the BBB; transfers the process of glucose breakdown to an energy-efficient, aerobic pathway; selectively blocks Ca2+ – dependent phosphodiesterase; increases the levels of AMP and cGMP in the brain. Increases the concentration of ATP in brain tissues; increases the exchange of norepinephrine and serotonin in the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of red blood cells and blocks the utilization of adenosine by red blood cells; promotes increased oxygen release by red blood cells.

Enhances the neuroprotective effect of adenosine. Increases cerebral blood flow; reduces the resistance of cerebral vessels without significantly changing the indicators of systemic circulation (blood pressure, minute volume, heart rate, total peripheral resistance).

Not only does it not have the effect of “stealing”, but it also increases blood supply, primarily in ischemic areas of the brain with low perfusion.

Indications

Ophthalmology: chronic vascular diseases of the choroid and retina of the eye.

For the treatment of perceptual hearing loss, Meniere’s disease, idiopathic tinnitus.

Neurology: reducing the severity of neurological and mental symptoms in various forms of circulatory insufficiency of the brain.

Use during pregnancy and lactation

Contraindicated in pregnancy. Vinpocetine penetrates the placental barrier.

At the same time, its concentration in the placenta and fetal blood is lower than in the blood of a pregnant woman.

At high doses, placental bleeding and spontaneous abortions are possible, probably as a result of increased placental blood supply.

Within an hour,0.25% of the taken dose of the drug penetrates into breast milk.

When using the drug, it is necessary to stop breastfeeding.

Contraindications

acute phase of hemorrhagic stroke; severe CHD; severe arrhythmias; pregnancy; lactation; children under 18 years of age (due to insufficient data); lactose intolerance; hypersensitivity to vinpocetine.

Side effects

Side effects associated with the use of the drug were rarely detected.

From the cardiovascular system: ECG changes (ST depression, prolongation of the QT interval); tachycardia, extrasystole, but the presence of a causal relationship is not proven, since in the natural population these symptoms are observed with the same frequency; changes in blood pressure (more often a decrease), skin hyperemia, phlebitis.

From the central nervous system: sleep disorders (insomnia, increased drowsiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn. Other: allergic skin reactions; increased sweating.

Interaction

Not observed when used concomitantly with pindolol, clopamide, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide; imipramine.

In rare cases, concomitant use with alpha-methyldopa is accompanied by a slight increase in the antihypertensive effect, with the use of such a combination, regular blood pressure monitoring is necessary.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when prescribing concomitantly with drugs of central, antiarrhythmic and anticoagulant action.

How to take, course of use and dosage

Inside, after eating. Usually the daily dose is 5-10 mg 3 times a day (15-30 mg per day). The initial daily dose is 15 mg. The maximum daily dose is 30 mg. The therapeutic effect develops approximately one week after the start of taking the drug. The course of treatment is 1-3 months.

In diseases of the kidneys and liver, the drug is prescribed in the usual dose, the absence of accumulation allows for long courses of treatment.

Overdose

Currently, data on vinpocetine overdose are limited.

Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Special instructions

Cavinton does not have a hepatotoxic and nephrotoxic effect, so when prescribing the drug to patients with liver and kidney diseases, no dosage adjustment is required.

In case of lactose intolerance, it should be noted that each tablet contains 83 mg of lactose.

Use in pediatrics

It is not recommended to prescribe the drug to children under the age of 18 years due to the lack of experience in using Cavinton in this category of patients.

Form of production

Tablets

Storage conditions

The drug should be stored in a place protected from light, out of the reach of children at a temperature of 15° to 30°C.

Shelf

life is 5 years.

Active ingredient

Vinpocetine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets